MK-8504 / Merck (MSD) - LARVOL DELTA

Approved HIV reverse transcriptase inhibitors in the past decade. (PubMed, Acta Pharm Sin B) - "Here, we provide a comprehensive review of RT inhibitors (tenofovir alafenamide, rilpivirine, doravirine, dapivirine, azvudine and elsulfavirine) approved in the past decade, regarding their drug discovery, pharmacology, and clinical efficacy in randomized controlled trials. Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains."

Journal • Review • Human Immunodeficiency Virus • Immunology • Infectious Disease

[VIRTUAL] MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV (CROI 2020) - "The persistent adequate concentrations of TFV-DP belie the poor VL response; it is possible, though, that VL responses could improve with daily administration of MK-8504 or MK-8583. Collectively, these data raise questions about the feasibility of TFV prodrugs in extended-interval dosing regimens."

MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV INFECTION (CROI 2020) - No abstract available